Price Subsidy Schemes for Artemisinin-Based Combination Therapies (ACTs): Do They Work?

Gavin Yamey & Marco Schäferhoff | 05 Apr 2011
Evidence to Policy Initiative (E2Pi)
Although ACT s are recommended as first line treatment for uncomplicated malaria, actual use of ACT is very limited, partly due to its high price in pharmacies and retail stores. The Affordable Medicines Facility-malaria (AMFm), a donor-funded global price subsidy, has been proposed as a strategy to increase ACT use in malaria-endemic countries. Given that donor-supported ACT subsidy schemes are costly, it is crucial to ensure that they have their intended impact. In this Policy Brief, E2Pi reviews the available literature evaluating whether previous private sector ACT subsidy schemes have worked or not. The brief also discusses the implications of these schemes for the initial two-year AMF m pilot phase (Phase 1).

Full Policy Brief available at